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ABSTRACT
1-Adrenergic receptor activation stimulates cardiac L-type
Ca2 channels via adenylyl cyclases (ACs), with AC5 and AC6
being the most important cardiac isoforms. Recently, we have
identified 2(3)-O-(N-methylanthraniloyl)-guanosine 5-[-thio-
]triphosphate (MANT-GTPS) as a potent competitive AC in-
hibitor. Intriguingly, MANT-GTPS inhibits AC5 and -6 more
potently than other cyclases. These data prompted us to study
the effects of MANT-GTPS on L-type Ca2 currents (ICa,L) in
ventricular myocytes of wild-type (WT) and AC5-deficient
(AC5/) mice by whole-cell recordings. In wild-type myocytes,
MANT-GTPS attenuated ICa,L stimulation following isoproter-
enol application in a concentration-dependent manner (control,
77  13%; 100 nM MANT-GTPS, 43  6%; 1 M MANT-
GTPS, 21  9%; p  0.05). The leftward shift of current-
voltage curves was abolished by 1 M but not by 100 nM
MANT-GTPS. In myocytes from AC5/ mice, the residual
stimulation of ICa,L was not further attenuated by the nucleotide,
indicating AC5 to be the major AC isoform mediating acute
-adrenergic stimulation in WT mice. Interestingly, basal ICa,L
was lowered by 1 M but not by 100 nM MANT-GTPS. The
decrease was less pronounced in myocytes from AC5/ mice
compared with wild types (23 1 versus40 7%), indicating
basal ICa,L to be partly driven by AC5. Collectively, we found a
concentration-dependent inhibition of ICa,L by MANT-GTPS,
both under basal conditions and following -adrenergic stimula-
tion. Comparison of data from wild-type and AC5-deficient mice
indicates that AC5 plays a major role in ICa,L activation and that
MANT-GTPS predominantly acts via AC5 inhibition.
1-Adrenoreceptor activation via the stimulatory G protein
GS leads to enhanced cAMP generation catalyzed by adeny-
lyl cyclases (ACs). cAMPmediates diverse cellular responses,
e.g., by activating protein kinase A. One target for phosphor-
ylation by protein kinase A is the cardiac L-type Ca2 chan-
nel (Kamp and Hell, 2000). At least 10 mammalian AC iso-
forms with a tissue-specific distribution have been identified
(Hanoune and Defer, 2001). In mammalian heart the Ca2-
dependent isoforms AC5 and AC6 are the two main cyclase
isoforms at the mRNA level. Besides AC5 and AC6, several
other AC isoforms (types 2, 3, 4, 7, and 9) were found in
murine hearts (Okumura et al., 2003a), but they are thought
to play a negligible functional role due to low expression
levels or low enzymatic activity (Defer et al., 2000; Hanoune
and Defer, 2001).
Although AC5 represents the isoform with the highest
catalytic activity in the adult heart (Ishikawa et al., 1992), it
remains unclear whether it is the functionally dominant
cardiac isoform, in particular regarding acute regulation of
L-type Ca2 channel activity and thus modulation of Ca2
influx triggering contraction. Nevertheless, AC5 is an inter-
esting potential drug target in the therapy of heart disease.
In this regard, transgenic overexpression of type 6 AC did not
induce abnormal histological findings or deleterious changes
in the heart (Gao et al., 1999), whereas overexpression of
type 5 AC affects basal AC activity and cardiac function
(Tepe et al., 1999). These findings indicate that AC5, in
contrast to type 6 AC, plays an important role under patho-
logical conditions. Furthermore in AC5-knockout (AC5/)
mice, contractile properties and L-type Ca2 currents (ICa,L)
were impaired in a Ca2-dependent manner (Okumura et al.,
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2003a), whereas cardiac function was protected against pres-
sure overload induced by aortic banding (Okumura et al.,
2003b). Particularly, these findings on AC5 deficiency under-
line the important role of AC5 in murine hearts and suggest
AC inhibitors to be promising pharmacological tools and per-
haps even therapeutics. This notion is supported by the find-
ing that excessive activation of the 1-adrenoreceptor-
GS-AC cascade is detrimental for cardiac function
(Engelhardt et al., 1999; Lohse et al., 2003).
Most AC inhibitors known so far are either noncompetitive
or nonspecific regarding isoforms (Hanoune and Defer, 2001;
Iwatsubo et al., 2004). However, with respect to therapeutic
use, both competitiveness and isoform specificity would be
helpful properties in minimizing the risk of adverse effects.
Recently, we have identified 2(3)-O-(N-methylanthraniloyl)
(MANT) nucleotides as a novel class of potent competitive AC
inhibitors (Gille and Seifert, 2003). Intriguingly, MANT-nu-
cleotides inhibit AC5 and AC6 more potently than other
cyclases (Gille et al., 2004). Crystallographic, biophysical,
and biochemical studies have provided in-depth insight into
the molecular interactions of MANT-nucleotides with AC,
providing a rational basis for the development of even more
potent and selective AC inhibitors than those currently avail-
able (Mou et al., 2005, 2006).
To assess the pharmacological effects of MANT nucleotides
in murine cardiomyocytes, we took advantage of the pivotal
position of AC linking -adrenergic signaling to L-type Ca2
current stimulation. We used the hydrolysis-resistant
MANT-nucleotide MANT-GTPS (Fig. 1) as a prototypical
competitive AC inhibitor. During whole-cell patch-clamp re-
cordings, the membrane-impermeant compound was deliv-
ered by intracellular dialysis. Freshly isolated murine cardi-
omyocytes were exposed to isoproterenol to study AC5
inhibition under basal conditions and -adrenergic stimula-
tion. We repeated these experiments in AC5/ cardiomyo-
cytes to determine the AC5 specificity of the effects of MANT-
GTPS.
Materials and Methods
Animals. Mice (3–9 months old) with type 5 adenylyl cyclase
deficiency (AC5/) (Okumura et al., 2003b) were fully backcrossed
(more than five generations) into the C57/Bl6 strain and bred with
their respective nontransgenic littermates. Wild-type C57/Bl6 mice
(3–9 months old) served as control. Experiments complied with re-
spective laws and local regulations regarding animal care.
Genotyping of Knockout Mice. A tail-clip analysis was per-
formed at 3 to 4 weeks of age. After preparation of genomic DNA, a
polymerase chain reaction was run. To genotype AC5/, we used the
following primer pairs: wild type (), forward, 5-CGC TAC TTC
TTC CAC CTG AAC CAG-3; reverse, 5-TGA TAA GGA TCA CGC
CCA CAG C-3, and knockout (), forward, 5-TCG TGC TTT ACG
GTA TCG CCG CTC CCG ATT-3; reverse, 5-TGA TAA GGA TCA
CGC CCA CAG C-3. Both reactions were run over 40 cycles (satu-
ration). Amplified sequences were 157 base pairs for the WT allele
and 443 base pairs for the targeting construct.
Isolation of Cardiac Myocytes. Single ventricular myocytes
were isolated by enzymatic dissociation using the method described
previously (Foerster et al., 2003). In brief, hearts were perfused with
a collagenase solution (Worthington type I and II, 75 U/ml; Cell
Systems, St. Katharinen, Germany) in a Langendorff setup, and they
were subsequently cut into small chunks. Myocytes were harvested
by pouring the suspension through cheesecloth.
Whole-Cell Recording. L-type calcium channel currents were
measured at room temperature using the whole-cell configuration of
the patch-clamp technique as described previously (Heubach et al.,
2001). Whole-cell experiments were performed in an external solu-
tion containing 137 mM NaCl, 5.4 mM CsCl, 2 mM CaCl2, 1.25 mM
Fig. 2. Effect of 1 M MANT-GTPS on basal L-type Ca2 current in
wild-type murine cardiomyocytes. A, original traces in the absence and
presence of 1 M MANT-GTPS at the time points 0 and 10 min. B,
averaged time course of whole-cell L-type Ca2 current density in the
absence (filled symbols; n 6) and in the presence of 1 MMANT-GTPS
(open symbols; n  6). Starting from a holding potential of 60 mV the
current was elicited by a test potential of  10mV preceded by a prepulse
to 40 mV.
Fig. 1. Structural formula of MANT-GTPS. Note the spontaneous
isomerization between the 2- and 3-MANT-substituted structure.
Inhibition of Cardiac Adenylyl cyclase by MANT-GTPS 609
MgCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4 with NaOH.
Pipettes (1.5 to 3-M borosilicate glass) were filled with 140 mM
CsCl, 4 mM MgCl2, 10 mM HEPES, 10 mM EGTA, and 4 mM
Na2ATP, pH 7.3 with CsOH. Cells were continuously superfused
with drug-free bath solution, and then they were switched to a
solution containing 100 nM ()-isoproterenol. Gigaohm seals were
formed by gentle suction. The seal resistances were usually between
2 and 5 G. Before series resistance compensation, membrane ca-
pacitance was measured by means of fast depolarizing ramp pulses
(from 40 to 35 mV; 5-ms duration) at the beginning of each
experiment. Compensated access resistance was regularly checked
and maintained below 5 M. Series resistance was routinely com-
pensated by 50 to 70%. Membrane currents were low-pass filtered at
2 kHz. Only rod-shaped myocytes with clear striation were used.
Whole-cell Ca2 currents were elicited by 200-ms depolarizing volt-
age steps from a holding potential of 60 mV. The stimulation
frequency was 0.2 Hz (EPC-9; HEKA, Lambrecht/Pfalz, Germany).
For each cell, a current-voltage relationship was established at the
beginning and the end of the experiment. The test potential was10
mV. For isolation of ICa,L from contaminating currents, sodium and
T-type calcium currents were inactivated by a 50-ms-long prepulse to
40 mV (holding potential 60 mV), and K currents were mini-
mized by replacing K with Cs. To account for variability in cell
size, absolute current amplitudes [in picoamperes (pA)] were divided
by the respective cell capacitance [in picofarads (pF)], and values are
expressed as membrane current I in picoamperes per picofarads. The
software PULSE, version 9.12 (HEKA) was used for data acquisition.
Drugs.MANT-GTPS (Jena Bioscience, Jena, Germany) and ()-
isoproterenol HCl (Sigma Chemie, Deisenhofen, Germany) were pre-
pared as 10 mM stock solutions in double-distilled H2O. Isoprotere-
nol was further diluted in bath solution and superfused the
cardiomyocytes using a rapid solution changer (RSC 200; Bio-Logic,
Fig. 3. Effect of 1 M MANT-GTPS on isoproterenol-stimulated L-type Ca2 current in wild-type murine cardiomyocytes. Cells were superfused by
isoproterenol containing bath solution for 12.0  0.1 min (control) and 13.0  0.2 min (MANT-GTPS), respectively. A, original traces before and after
100 nM ()-isoproterenol stimulation and in the absence and presence of 1 M MANT-GTPS at the time point 0 min and at the maximal increase
of L-type Ca2 current. B, averaged time course of whole-cell L-type Ca2 current density from experiments with murine ventricular myocytes before
and after 100 nM ()-isoproterenol stimulation and in the absence (filled symbols; n  5) and in the presence of 1 M MANT-GTPS (open symbols;
n 5). Starting from a holding potential of60 mV, the current was elicited by a test potential of10 mV preceded by a prepulse to40 mV. C, control
current density-voltage relationship in the absence (filled symbols; n  5) and in the presence (open symbols; n  5) of 100 nM ()-isoproterenol,
measured before and 10 min after start of isoproterenol application. D, current density-voltage relationship with 1 M MANT-GTPS diluted in the
pipette solution in the absence (filled symbols; n 5) and in the presence (open symbols; n 5) of 100 nM ()-isoproterenol measured at the beginning
and at the end of the experiments. , p  0.05 (alternate t test).
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Claix, France). MANT-GTPS was diluted in pipette solution imme-
diately before use.
Statistics and Data Analysis. Results are given as mean val-
ues  S.E.M. Differences between mean values were tested by alter-
nate t test and considered statistically significant for p  0.05.
Results
Effect of MANT-GTPS on Basal ICa,L in Wild-Type
Myocytes. We first wanted to assess the effect of MANT-
GTPS on basal currents mediated by L-type Ca2 channels
in wild-type ventricular myocytes. Under control conditions,
ICa,L showed a slight decrease that did not exceed 8% of the
initial current within 10 min, and it reached stable values for
the remaining recording time (from 4.8  0.3 pA/pF to
4.4  0.25 pA/pF after 10 min; N.S., n  6; Fig. 2B). When
1 M MANT-GTPS was present in the pipette solution,
current density was not instantaneously different compared
with control recordings, but it decreased significantly over
time (Fig. 2, A and B). After 10 min of recording with MANT-
GTPS in the pipette, current density was lowered by 40  7%
(Fig. 2, A and B; from 4.0  0.24 pA/pF to 2.5  0.3 pA/pF;
p  0.05, n  6). This demonstrates that 1 M MANT-GTPS
reduced basal L-type Ca2 current as a function of time, due to
intracellular dialysis via the patch pipette. The reduction of
basal L-type Ca2 channel activity reached a plateau after 12 to
15 min of recording, suggesting that the reduction of L-type
Ca2 current is not due to continuous “run-down.”
Effects of MANT-GTPS on ICa,L Stimulation by Iso-
proterenol in Wild-Type Myocytes. Isoproterenol is
known to stimulate currents mediated by L-type Ca2 chan-
nels due to increased protein kinase A activity following
enhanced cAMP production catalyzed by AC. We therefore
obtained ICa,L stimulated by isoproterenol in the absence and
the presence of the AC inhibitor MANT-GTPS at 1 M.
Under control conditions, 100 nM isoproterenol increased
maximal ICa,L by 77%. This increase was attenuated to only
21% in the presence of MANT-GTPS (77  13 versus
21  9%; p  0.01, n  10; Figs. 3, A and B, and 5D). When
MANT-GTPS was applied, the leftward-shift of I/V curves
typically caused by isoproterenol was absent (Fig. 3, C and
D). It is noteworthy that after 15 min of isoproterenol perfu-
sion, currents still were significantly increased above pre-
drug values in the absence of MANT-GTPS. In contrast, in
the presence of the AC inhibitor, current density declined
below values obtained before drug application (Fig. 3B). This
could be due to an ongoing reduction of basal current, of
isoproterenol-stimulated current, or both. To discriminate
between these possibilities, washout experiments were per-
formed. Isoproterenol was applied early in the course of the
experiment and washed out 10 min later (Fig. 4, A and B).
Compared with controls (Fig. 4B), calcium current decrease
by isoproterenol washout was less pronounced in the pres-
ence of MANT-GTPS, indicating smaller remaining agonist
effect at that time. These data match our findings showing a
decrease in current density by MANT-GTPS even in the
absence of -adrenergic stimulation (see above). In summary,
MANT-GTPS significantly and almost completely dimin-
ished the increase of ICa,L due to isoproterenol.
Concentration Dependence of MANT-GTPS Effects
on ICa,L in Wild-Type Myocytes. MANT-GTPS inhibited
isoproterenol effects in a concentration-dependent way. A
lower concentration of the MANT-nucleotide, 100 nM, still
reduced the increase in ICa,L due to 100 nM isoproterenol
stimulation (Fig. 5A), albeit to a lower extent (control,77 
13%; 100 nM MANT-GTPS, 43  6%; and 1 M MANT-
GTPS, 21  9%; Fig. 5D). It is noteworthy that in the
presence of the lower MANT-GTPS concentration, isopro-
terenol still caused the typical leftward shift of the I/V curve
as observed under control conditions (Fig. 5C). Interestingly,
8 min after starting 100 nM isoproterenol perfusion, stimu-
lated ICa,L remained stable in the presence of 100 nMMANT-
GTPS, suggesting that no further decrement of the isopro-
terenol effect was caused by the low nucleotide concentration
(Fig. 5, A and B). These findings also suggest that lower
concentrations of the nucleotide did not affect basal ICa,L. To
evaluate the effect of 100 nM MANT-GTPS on basal ICa,L, a
comparison of current values immediately before starting
isoproterenol perfusion (at 2.5 min) was performed. Under
control conditions (4  2%) and in the presence of 100 nM
Fig. 4. Reversibility of the effect of isoproterenol on L-type Ca2 current
in wild-type murine cardiomyocytes. A, averaged time course of whole-
cell L-type Ca2 current density from experiments with myocytes before
and after 100 nM ()-isoproterenol stimulation, followed by isoproterenol
washout in the presence of 1 M MANT-GTPS (filled symbols; n  5).
Open symbols show basal L-type Ca2 current time course (cf. Fig. 2B) to
illustrate reversibility of isoproterenol stimulation in the presence of
MANT-GTPS. Starting from a holding potential of 60 mV the current
was elicited by a test potential of 10 mV preceded by a prepulse to 40
mV. B, filled symbols represent the averaged (n  5) time course of
similar washout experiments, performed in the absence of MANT-
GTPS.
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MANT-GTPS (3  2%; N.S. versus control), currents were
unaffected; 1 M MANT-GTPS decreased current by al-
ready 19  4% (p  0.01 versus control; n  5). This
confirms that lower concentrations of MANT-GTPS did not
affect basal ICa,L. In summary, basal and isoproterenol-stim-
ulated inhibition of ICa,L in the presence of MANT-GTPS is
concentration-dependent.
Effect of MANT-GTPS on Basal ICa,L in AC5
/Myo-
cytes. To determine AC5-specific effects of MANT-nucleo-
tides and to characterize the functional role of AC5, experi-
ments obtained with WT cardiomyocytes were repeated in
ventricular myocytes from mice lacking AC5 (AC5/). In
ventricular myocytes from AC5/ mice, 1 M MANT-
GTPS decreased ICa,L (after 10 min, 23  1 versus 8  2%
without MANT-GTPS; p 0.01, n 6; Fig. 6, A and B). This
reduction of basal ICa,L in AC5
/myocytes was significantly
less pronounced than in WT myocytes (after 10 min, 41 
7%; p  0.05, n  6), indicative for an AC5-specific effect of
MANT-GTPS.
Effects of MANT-GTPS on ICa,L Stimulation by Iso-
proterenol in AC5/ Myocytes. In accordance with pre-
vious findings (Okumura et al., 2003a) isoproterenol effects
on ICa,L were mitigated in ventricular myocytes of AC5
/
mice. It is noteworthy that MANT-GTPS at 1 M did not
further attenuate ICa,L stimulated by isoproterenol in
AC5/myocytes (32  3 versus 29  3%; N.S., n  5; Fig. 7,
A–C). Toward the end of incubation, isoproterenol effects
seemed to decrease in the presence of MANT-GTPS. How-
Fig. 5. Effect of 100 nM MANT-GTPS on isoproterenol-stimulated L-type Ca2 current in wild-type murine cardiomyocytes. Cells were superfused
by isoproterenol containing bath solution for 8.4 0.1 min. A, original traces before and after 100 nM ()-isoproterenol stimulation and in the presence
of 100 nM MANT-GTPS at the time point 0 min and at the maximal increase of L-type Ca2 current. B, averaged time course of whole-cell L-type
Ca2 current density from experiments with murine ventricular myocytes before and after 100 nM ()-isoproterenol stimulation in presence of 100
nMMANT-GTPS (filled symbols; n 5). Starting from a holding potential of60 mV, the current was elicited by a test potential of10 mV preceded
by a prepulse to 40 mV. C, current density-voltage relationship with 100 nM MANT-GTPS diluted in the pipette solution in the absence (filled
symbols; n  5) and in the presence (open symbols; n  5) of 100 nM ()-isoproterenol measured at the beginning and at the end of the experiments,
respectively. , p 0.05 (alternate t test). D, maximal increase of L-type Ca2 current density by isoproterenol (percentage of predrug values) compared
with basal current in the absence (black bar; n  10) and in the presence of 100 nM (gray bar; n  5) or 1 M (white bar; n  11) MANT-GTPS,
respectively. , p  0.05 versus control (alternate t test).
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ever, subtraction of the basal ICa,L time course (cf. Fig. 6B)
from isoproterenol-stimulated ICa,L revealed that this effect
is entirely explained by the reduction in basal L-type Ca2
current activity (data not shown). The MANT-GTPS resis-
tance of isoproterenol effects in AC5/ myocytes was con-
firmed by nearly unaffected I/V curves (Fig. 7, D and E).
Discussion
In our present study, we characterized the effect of the
novel competitive AC inhibitor MANT-GTPS on murine
ventricular ICa,L. MANT-GTPS is well suited for electro-
physiological studies using intracellular dialysis because it is
hydrolysis-resistant. Our findings indicate AC5 to be the
major functional isoformmediating acute 1-adrenergic stim-
ulation of ICa,L. In the presence of MANT-GTPS, we find an
attenuation of ICa,L increase following -adrenergic stimula-
tion via isoproterenol, confirming previous findings obtained
with AC5-deficient mice (Okumura et al., 2003a). Most im-
portantly, we found that in AC5-deficient mice, 1 MMANT-
GTPS did not further attenuate maximal ICa,L response to
isoproterenol. Considering the similar affinities of MANT-
GTPS to the cardiac isoforms AC5 and AC6 (Gille et al.,
2004), we conclude that AC5 plays a major role in mediating
immediate -adrenergic stimulation of L-type Ca2 channels
in ventricular cardiomyocytes.
Using the lower concentration of MANT-GTPS, 100 nM, a
moderate inhibition of isoproterenol effects was obtained
without concomitant inhibition of basal currents. Further-
more, ICa,L increase following isoproterenol was maintained
here, whereas in the presence of 1 M nucleotide, ICa,L de-
creased continuously during the course of experiments. This
indicates that the isoproterenol-stimulated current is more
sensitive toward the AC inhibitor than the basal current. The
only minimal effect of MANT-GTPS on basal current in
AC5-deficient mice reveals that part of the inhibition of basal
current in WT mice is due to AC5 inhibition. Additional
mechanisms, such as involvement of a less sensitive func-
tional AC isoform in basal current regulation, or other non-
specific effects of the nucleotide cannot be further elucidated
by our experiments. Thus, our data reveal AC5 to activate
tonically basal Ca2 current activity. This interpretation
might at first glance contrast to the unchanged basal current
values reported for AC5/ mice by group comparison (Oku-
mura et al., 2003a), but long-term compensatory mechanisms
are to be expected in such genetic models. Considering the
lower isoproterenol effect on ICa,L in AC5
/ myocytes, one
might also speculate on decreased abundance of potential
phosphorylation sites, e.g., by lower expression of the pore-
forming, protein kinase A-sensitive 1C subunit coded by
exon 1a (van der Heyden et al., 2005) or altered composition
of the heteromeric channel complex by pore-forming 1C and
auxiliary -subunits (Bu¨nemann et al., 1999).
MANT-nucleotides represent novel experimental tools in
the search for potential therapeutic compounds because they
are competitive AC inhibitors (Gille and Seifert, 2003). Re-
cent high-resolution crystallographic data underline their
eminent role as lead compounds for the development of po-
tent and isoform-specific AC inhibitors (Mou et al., 2005,
2006). Our present data show that isoproterenol effects are
reduced by MANT-GTPS via concentration-dependent inhi-
bition of AC5. Considering the sympathetic overdrive in
heart failure, this indicates MANT-nucleotides as promising
starting points regarding innovative therapeutic strategies.
MANT-GTPS as a prototypical competitive AC inhibitor
shows AC5-mediated effects, as proven by its lack of effect on
isoproterenol-stimulation of ICa,L in AC5
/ cardiomyocytes.
Because AC5 deficiency seems to be protective against heart
failure due to pressure overload (Okumura et al., 2003b), this
demonstrates that MANT-nucleotides could serve as a novel
approach in the therapy of cardiac diseases. This is sup-
ported by the known benefits of -adrenoceptor antagonists
in the treatment of heart failure. -Adrenoceptor antagonists
have become standard treatment of heart failure, although it
is unclear what the exact underlying mechanism is. Some
data suggest that signaling via 2-adrenoceptors would be
beneficial (Dorn et al., 1999; Du et al., 2000), whereas 1-
adrenoceptor signaling obviously is detrimental (Engelhardt
et al., 1999; Lohse et al., 2003). This divergence is supported
by findings on the differential signaling cascades and L-type
Fig. 6. Effect of 1 M MANT-GTPS on basal L-type Ca2 current in
AC5/ murine cardiomyocytes. A, original traces in the absence and
presence of 1 M MANT-GTPS at the time points 0 and 10 min. B,
averaged time course of whole-cell L-type Ca2 current density from
experiments with murine ventricular myocytes lacking type 5 AC
(AC5/) in the absence (filled symbols; n  6) and in the presence of 1
M MANT-GTPS (open symbols; n  6). Starting from a holding poten-
tial of 60 mV the current was elicited by a test potential of 10 mV
preceded by a prepulse to 40 mV.
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Ca2 channel regulation by 1- and 2-adrenoceptors (Foer-
ster et al., 2003, 2004; Xiao et al., 2006). A major difference is
dual signaling via Gi and Gs proteins by 2-adrenoceptors,
and only Gs in case of 1-adrenoceptors. Hence, adenylyl
cyclase inhibitors might be an attractive alternative to -ad-
renoceptor antagonists due to their selective prevention of an
(excessive) increase of cAMP.
In future studies, we will have to design potent cell-per-
meable AC5 inhibitors because the currently available AC
inhibitors are not cell membrane-permeable. A feasible ap-
proach is the design of pronucleotides that can be deprotected
and phosphorylated within cells (Laux et al., 2004). More-
over, we have already shown that MANT-nucleoside 5-
diphosphates are phosphorylated to the corresponding triphos-
phates by cellular kinases (Gille et al., 2004). It should be
emphasized that the concept of AC5 inhibition for the treatment
of cardiovascular disease is quite different from the current
concept of 1-adrenoceptor blockade because ACs integrate the
input from multiple receptor systems (Hanoune and Defer,
2001). Our present study shows that the combination of phar-
macological studies with gene knockout studies is very powerful
at delineating signal transduction pathways and establishing
novel therapeutic concepts.
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Fig. 7. Effect of 1 M MANT-GTPS on isoproterenol-stimulated L-type Ca2 current in AC5/ murine cardiomyocytes. Cells were superfused by
isoproterenol containing bath solution for 8.2  0.1 min (control) and 8.2  0.1 min (MANT-GTPS), respectively. A, original traces before and after
100 nM ()-isoproterenol stimulation and in the absence and presence of 1 M MANT-GTPS at the time point 0 min and at the maximal increase
of L-type Ca2 current. B, averaged time course of whole-cell L-type Ca2 current density from experiments with murine ventricular myocytes lacking
type 5 AC (AC5/) before and after 100 nM ()-isoproterenol stimulation and in the absence (filled symbols; n  5) and in the presence of 1 M
MANT-GTPS (open symbols; n  5). Starting from a holding potential of 60 mV, the current was elicited by a test potential of 10 mV preceded
by a prepulse to 40 mV. C, maximal increase of L-type Ca2 current density (percentage) compared with basal current (0) in the absence (black
bar; n  5) and in the presence (white bar; n  5) of 1 M MANT-GTPS. D, control current density-voltage relationship from AC5/ myocytes in
the absence (filled symbols; n  5) and in the presence (open symbols; n  5) of 100 nM ()-isoproterenol measured at the beginning and at the end
of the experiments. E, current density-voltage relationship from AC5/ myocytes with 1 M MANT-GTPS diluted in the pipette solution in the
absence (filled symbols; n  5) and in the presence (open symbols; n  5) of 100 nM ()-isoproterenol measured at the beginning and at the end of
the experiments, respectively.
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